{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:34:47Z","timestamp":1761863687736},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10147-017-1118-x","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T13:26:06Z","timestamp":1491398766000},"page":"690-697","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"22","author":[{"given":"Haruki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095\u20132103","journal-title":"J Clin Oncol"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. doi:\n                        10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"1118_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. doi:\n                        10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"suppl","key":"1118_CR4","first-page":"abstr8027","volume":"33","author":"N Makoto","year":"2015","unstructured":"Makoto N, Toyoaki H, Kazuhiko N et al (2015) Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). J Clin Oncol 33(suppl):abstr8027","journal-title":"J Clin Oncol"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. doi:\n                        10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. doi:\n                        10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. doi:\n                        10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. doi:\n                        10.1038\/nature13954","journal-title":"Nature"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124\u2013128. doi:\n                        10.1126\/science.aaa1348","journal-title":"Science"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. doi:\n                        10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463\u20131469. doi:\n                        10.1126\/science.aaf1490","journal-title":"Science"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. doi:\n                        10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"1118_CR13","first-page":"vi552","volume":"27","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Park K, Ciardiello F et al (2016) Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L\/3L NSCLC. Ann Oncol 27[Suppl 6]:vi552\u2013vi587","journal-title":"Ann Oncol"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"7941","DOI":"10.1158\/0008-5472.CAN-07-1622","volume":"67","author":"M Obeid","year":"2007","unstructured":"Obeid M, Panaretakis T, Tesniere A et al (2007) Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from \u201csilent\u201d to immunogenic. Cancer Res 67:7941\u20137944. doi:\n                        10.1158\/0008-5472.CAN-07-1622","journal-title":"Cancer Res"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050\u20131059. doi:\n                        10.1038\/nm1622","journal-title":"Nat Med"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","volume":"8","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151\u2013160. doi:\n                        10.1038\/nrclinonc.2010.223","journal-title":"Nat Rev Clin Oncol"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26:234\u2013241. doi:\n                        10.1259\/0007-1285-26-305-234","journal-title":"Br J Radiol"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee Y, Auh SL, Wang Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8\u00a0+\u00a0T cells: changing strategies for cancer treatment. Blood 114:589\u2013595. doi:\n                        10.1182\/blood-2009-02-206870","journal-title":"Blood"},{"key":"1118_CR19","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA et al (2005) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516\u20137523","journal-title":"J Immunol"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-06-1772","volume":"13","author":"NJ Nesslinger","year":"2007","unstructured":"Nesslinger NJ, Sahota RA, Stone B et al (2007) Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13:1493\u20131502. doi:\n                        10.1158\/1078-0432.CCR-06-1772","journal-title":"Clin Cancer Res"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-07-4462","volume":"14","author":"D Schaue","year":"2008","unstructured":"Schaue D, Comin-Anduix B, Ribas A et al (2008) T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 14:4883\u20134890. doi:\n                        10.1158\/1078-0432.CCR-07-4462","journal-title":"Clin Cancer Res"},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS et al (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306\u20131310. doi:\n                        10.1016\/j.ijrobp.2011.09.049","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379\u20135388. doi:\n                        10.1158\/1078-0432.CCR-09-0265","journal-title":"Clin Cancer Res"},{"key":"1118_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nature09004","volume":"465","author":"W Lee","year":"2010","unstructured":"Lee W, Jiang Z, Liu J et al (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473\u2013477. doi:\n                        10.1038\/nature09004","journal-title":"Nature"},{"key":"1118_CR25","doi-asserted-by":"publisher","first-page":"e15661","DOI":"10.1371\/journal.pone.0015661","volume":"5","author":"B Timmermann","year":"2010","unstructured":"Timmermann B, Kerick M, Roehr C et al (2010) Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 5:e15661. doi:\n                        10.1371\/journal.pone.0015661","journal-title":"PLoS One"},{"key":"1118_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"N Cancer Genome Atlas","year":"2012","unstructured":"Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330\u2013337. doi:\n                        10.1038\/nature11252","journal-title":"Nature"},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433\u2013440. doi:\n                        10.1001\/jamaoncol.2015.1184","journal-title":"JAMA Oncol"},{"key":"1118_CR28","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","volume":"34","author":"S Gettinger","year":"2016","unstructured":"Gettinger S, Rizvi NA, Chow LQ et al (2016) Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung Cancer. J Clin Oncol 34:2980\u20132987. doi:\n                        10.1200\/JCO.2016.66.9929","journal-title":"J Clin Oncol"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585\u20134593. doi:\n                        10.1158\/1078-0432.CCR-15-3101","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1118-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T17:41:42Z","timestamp":1501263702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1118-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]}}}